RxDoctor Payments Data

Douglas Vogeler, MD

Family Medicine · Sandy, UTNPI 1790869550

Payments from drug & device makers

$8,625in general payments, 2019–2025

Across 478 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Amgen$709
  • Lilly USA, LLC$520
  • Novartis$331
  • Novo Nordisk$306
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$8,56299%
  • Education$370%
  • Entertainment$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,625 in reported general payments places this provider in the 90th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$85,318
Medicare patients
187
Services billed
1,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$62,986
XareltoRivaroxaban32$49,217
FarxigaDapagliflozin Propanediol11$14,835
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$13,832
Bydureon BciseExenatide Microspheres11$10,454
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$8,979
Ezetimibe381$8,080
Rosuvastatin Calcium628$7,717
Xigduo XrDapaglifloz Propaned/Metformin12$7,012
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,943
Ipratropium Bromide106$6,225
Omeprazole335$6,200
Bupropion XlBupropion Hcl119$4,399
Levothyroxine Sodium366$4,363
Celecoxib60$4,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$185$62,98661 claims
Johnson & JohnsonXarelto$271$49,21732 claims
AstraZenecaFarxiga$1,130$14,83511 claims
Boehringer IngelheimStiolto Respimat$42$6,94311 claims
MerckAsmanex$178$3,65517 claims
AbbVieSynthroid$2,184$1,71131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 928 family medicine providers in Utah.

Other family medicine in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →